Genmab in new platform collaboration
Genmab has agreed to collaborate with a Japanese pharmaceutical company concerning one of the Danish biotech company’s technologies.
by Kresten Morten Munksgaard
Genmab has entered into a new research collaboration with Japanese company Kyowa Hakko Kirin aimed at developing bispecific antibodies from Genmab’s DuoBody technology, the Danish company announces in a stock market release.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler:
Genmab-CEO: Janssen is the ideal partner
For abonnenter
Genmab in potential million-dollar-deal with US company
For abonnenter
New Genmab-deal with limited results
For abonnenter
